Brokerage Radar: Top Analyst Targets on Adani Ports, Lupin, Britannia, and 8 Other Stocks Today

Major global and domestic brokerages—including HSBC, Bernstein, Citi, Morgan Stanley, and Macquarie—have released updated coverage and target prices on 11 prominent Indian stocks. Featuring contrasting views on pharmaceutical major Lupin, major insights on consumer goods input costs, and robust growth upgrades for infrastructure giants, these analyst recommendations are poised to drive stock market action.

Consumer Goods: Sugar Inflation Pressures Britannia and Nestlé

According to Goldman Sachs (GS), a sharp rise in domestic sugar prices poses cost headwinds for consumer companies, with Britannia Industries expected to take the heaviest hit due to its high exposure to both sugar and palm oil prices. Because a significant portion of Britannia's revenue comes from fixed-price point packs, passing on immediate cost hikes remains challenging. GS maintains a 'Neutral' rating with a target price of ₹6,000.

While Nestlé India and Varun Beverages face similar raw material pressures, Goldman Sachs notes they are better positioned to absorb the shock. GS holds a 'Neutral' rating on Nestlé India (Target: ₹1,575) and a bullish 'Buy' rating on Varun Beverages (Target: ₹550).

Infrastructure & Energy: Big Wins for Adani and GMR

• Adani Energy Solutions: Morgan Stanley has maintained an 'Overweight' rating with a target price of ₹1,943. Driven by robust order inflows that have already crossed 50% of base-case estimates for FY27, the company's transmission order book has expanded to a massive ₹85,000 crore.

• GMR Airports: Macquarie has assigned an 'Outperform' rating with a target price of ₹120, following AERA's approval of a ₹13,800 crore expansion capex for Hyderabad Airport, which will scale passenger capacity to 80 million.

• Adani Ports & Gujarat Pipavav: HSBC remains highly bullish on Adani Ports with a 'Buy' recommendation, citing improved earnings visibility and a potential valuation re-rating ahead of concession renewals. Gujarat Pipavav receives a 'Hold' rating supported by an attractive dividend yield of roughly 7%.

Pharma & Tech: Split Verdict on Lupin and Zydus Life

• Lupin (Divergent Views): Bernstein has issued an 'Outperform' rating with a target of ₹2,707, highlighting a favorable Kalydeco patent verdict granting Lupin 180 days of first-to-file exclusivity for Ivacaftor. Conversely, Citi has downgraded Lupin to a 'Sell' with a target of ₹2,050, citing expected headwinds in the US business and margin compression down to 20% by FY29.

• Zydus Life: Macquarie has an 'Outperform' rating with a target of ₹1,285, projecting EBITDA margins to expand from 24% to 28% backed by product mix enhancements and the anticipated FY28 launch of Saroglitazar.

• Dixon Technologies: HSBC maintains a 'Buy' rating with a target price of ₹16,000, viewing recent PLI policy adjustments favorably due to potential component-level upsides.

• UPL: DAM Capital has issued a 'Buy' recommendation with a target of ₹870, noting strong core performance led by Advanta and Superform, with an upcoming Advanta IPO acting as a key value-unlocking catalyst.